RARE

$26.38-$0.48 (-1.79%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$2.6B

99M shares

52-week range

$18.29 – $39.89

37% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Change$-61.62

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$749M	+12.7%	$-4.27	$-5.16–$-1.89	—	9
2027	$994M	+32.6%	$-0.72	$-3.70–$8.38	—	9
2028	$1.2B	+24.0%	$0.44	$-0.99–$2.51	59.4×	12
2029	$1.6B	+28.8%	$2.74	$2.20–$3.91	9.6×	9

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 3 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-04	$-1.22	$-0.90	+26.2%
2026-05-05	$-1.49	$-1.84	-23.7%
2026-02-12	$-1.20	$-1.29	-7.5%
2025-11-04	$-1.23	$-1.81	-47.2%
2025-08-05	$-1.27	$-1.17	+7.9%
2025-05-06	$-1.54	$-1.57	-1.9%
2025-02-13	$-1.32	$-1.39	-5.3%
2024-11-05	$-1.45

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
RAREUltragenyx Pharmaceutical Inc.	$26.86	-0.37%	$2.6B	—
AAPGAscentage Pharma Group International	$18.97	-0.05%	$1.8B	—
APGEApogee Therapeutics, Inc.	$134.55	-0.10%	$8.3B	—
CELCCelcuity Inc.	$92.08	+4.51%	$4.5B	—
CGONCG Oncology Inc.	$76.99	-0.05%

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

www.ultragenyx.com

Employees: 1,371
IPO / List date: Jan 31, 2014
HQ: NOVATO, CA

Held by traders on TradeandTell

No one on the platform currently holds RARE.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	561,700	$11.8M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded RARE yet.

$RARE chatter on StockTwits

Shawn Nielsen@ShawnnielsenBullish4h
$RARE rare opportunity for us here
View on StockTwits ↗
Emily@CalculatedSwingBullish14h
$RARE
View on StockTwits ↗
Quantumup@Quantumup1d
Raymond James reiterated $MNPR Outperform-$123 and said -- We continue to model ALXN1840 approval and launch in 2027—Remain Outperform rated on MNPR shares following 2Q26 update. $RARE $PRME ETON Vivet Therapeutics - PFE AZN TELO Orphalan Raymond James added—All eyes remain focused on the rolling NDA submission for ALXN1840 in Wilson disease, which was recently initiated in July and the company expects to complete in the coming months. Recall, this allows FDA to receive and begin reviewing specific application sections as they are submitted, but acceptance of the application and PDUFA date assignment cannot occur until the application is complete and fully received. ALXN1840 does have Fast Track designation, which could lead to a shorter review time once the application is complete. We continue to model ALXN1840 approval and launch in 2027.
View on StockTwits ↗
Lionel Pinto@soulseeker2d
$RARE what’s your price predictions if the two therapies are approved?
View on StockTwits ↗
Cas@Cascas0073d
$RARE finally, some life in this stock. Hopefully a run to $30 before the PDUFA date
View on StockTwits ↗
Luigi DT@LDT796d
$RARE why are they shorting this hugely?
View on StockTwits ↗
fkdkdc@captainheroAug 6
@GamblingFerret @theSmokingBuzzard what Alvelestat value? P2 finished more than 3 years ago. In that time you can start from P1 and get a drug approved. They still haven't found P3 partner. It's worthless. And now they are on the brink of reverse split and having to find some source of financing. Setrusumab failed p3, FDA will maybe say they have a path forward, but that's $RARE thing, not $MREO. And $RARE could have other priorities in the next couple of months. On their own fronts, UK requires P3 rerun, we have no news from EU. They seem to fail at everything they do. Only $RARE can save them. They need good news and they need it quick. It's very high risk bet and reward might not prove to be so good.
View on StockTwits ↗
Efi@BioHuntingTwitsAug 5
$RARE This is a joke. Very good earnings report, 2 FDA decisions on the way and it is going down This is a real trading or there is someone who wants this stock cheap?
View on StockTwits ↗
sigavax@BioSpecialOneBullishAug 5
$RARE I’m in
View on StockTwits ↗
Rich Goodden@RomuloSkagenAug 5
$RARE not great. Just tested $25. Was hoping for the start of a runup into the PDUFA.
View on StockTwits ↗
Filvul@FilvulAug 5
$RARE
View on StockTwits ↗
Merlintrader Trading Pub@MerlintraderAug 5
$RARE
View on StockTwits ↗
DonCorleone77@DonCorleone77Aug 5
$APPS $TVTX $ANET $RARE $BKNG AFTER-HOURS MOVERS: Currently Higher After Earnings: - Digital Turbine (APPS) up 30.6% - Travere Therapeutics (TVTX) up 13.9% - Arista Networks (ANET) up 11.1% - Ultragenyx (RARE) up 6.4% - Booking (BKNG) up 5.6% - Wynn Resorts (WYNN) up 4.7% - Paylocity (PCTY) up 3.3% Currently Also Higher: - Sight Sciences (SGHT) up 11.4% after receiving FDA 510(k) clearance of the Omni Ultra Surgical System Currently Lower After Earnings: - Teradata (TDC) down 16.0% - Atomera (ATOM) down 10.9% - ViaSat (VSAT) down 8.9% - Chemours (CC) down 7.4% - Match Group (MTCH) down 9.8% - Pinterest (PINS) down 8.6% - AMD (AMD) down 8.8% - Lucid Group (LCID) down 7.9% - DaVita (DVA) down 6.6% - SpaceX (SPCX) down 7.5% - Lattice Semiconductor (LSCC) down 4.5% - Coupang (CPNG) down 7.3%
View on StockTwits ↗
Merlintrader Trading Pub@MerlintraderAug 4
Ultragenyx ($RARE) Q2 2026 Stock Hub: Record $214M Revenue, Two PDUFAs and the GTX-102 Readout https://www.merlintrader.com/ultragenyx-pharmaceuticals-rare-stock-hub/
View on StockTwits ↗
Stocktwits Earnings@StocktwitsEarningsAug 4
$RARE Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.90 up 23.08% YoY • Reported revenue of $214M up 28.53% YoY • Ultragenyx Pharmaceutical Inc. reaffirms its 2026 full-year total revenue guidance of $730 million to $760 million, excluding potential new product launches, while remaining on track toward profitability in 2027.
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.